VivoSeq
Oncology

Recurrent Multiple Myeloma

10

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Recurrent Multiple Myeloma is an early-stage landscape with 10 programs across 3 companies. The most active players are Bristol-Myers Squibb, Johnson & Johnson, Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

10programs
Small molecule550%
Monoclonal antibody440%
Cell therapy110%

Modality classified for 91% of 11 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Terminated1 · 17%
Completed1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Recruiting·Alliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06465316·26 enrolled
Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
Recruiting·MMayo Clinic·Preclinical·NCT06785415·37 enrolled
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Not yet recruiting·National Cancer Institute (NCI)·Preclinical·NCT07463807·162 enrolled
A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting Therapy
Completed·—·Phase 1·NCT06203912·3 enrolled
Prehabilitation in Patients With Multiple Myeloma Receiving CAR-T Therapy
Terminated·MMayo Clinic·Preclinical·NCT07045727·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)